Reversible genetic switches could give cancer immunotherapy more precise control

AI Summary

Researchers coordinated by Velia Siciliano at the Italian Institute of Technology have developed a reversible genetic switch to control immune cells as they attack tumors. The approach could support more precise engineered immunotherapies for solid cancers, including melanoma and breast cancer.

A genetic switch that activates immune cells as they fight tumors: this is the new strategy developed by an international research team coordinated by Velia Siciliano at the Istituto Italiano di Tecnologia (IIT—Italian Institute of Technology) in Naples and described in the journal Nature Communications. The study marks another step toward engineering precise and more effective synthetic immunotherapies against solid tumors, such as melanoma and breast cancer.